



MATERIAL SAFETY DATA SHEET

Revision date: 07-Sep-2011

Version: 3.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Lipitor® (Atorvastatin Calcium) Tablets

Trade Name: Lipitor®
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as Lipid regulating agent.

2. HAZARDS IDENTIFICATION

Appearance: White film-coated tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: May cause eye irritation (based on components) .

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver.

Known Clinical Effects: Adverse effects associated with therapeutic use of atorvastatin include constipation, flatulence, upset stomach, and abdominal pain. Clinical use of this drug has caused changes in liver function, muscle pain, weakness.

EU Indication of danger: Not classified

Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Atorvastatin calcium	134523-03-8	Not Listed	R52/53	7.0
Calcium carbonate	471-34-1	207-439-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 2 of 8
Version: 3.0

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Simethicone emulsion	67762-90-7	Not Listed	Not Listed	*
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	*
Croscarmellose sodium	74811-65-7	Not Listed	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	*
Opadry white	NOT ASSIGNED	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove contaminated clothing and shoes. Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 3 of 8
Version: 3.0

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Atorvastatin calcium

Pfizer OEL TWA-8 Hr: 50 µg/m³

Calcium carbonate

Bulgaria OEL - TWA 10.0 mg/m³
France OEL - TWA 10 mg/m³
Latvia OEL - TWA 6 mg/m³
Poland OEL - TWA 10 mg/m³
Portugal OEL - TWA 10 mg/m³
Spain OEL - TWA 10 mg/m³

Magnesium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
4 mg/m³
Latvia OEL - TWA 2 mg/m³
OSHA - Final PELs - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Romania OEL - TWA 10 mg/m³
Spain OEL - TWA 10 mg/m³

Analytical Method: Analytical method available for Atorvastatin. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 4 of 8
Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablet	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Calcium carbonate

Rat Oral LD50 6450 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Polysorbate 80

Rat Oral LD50 25 g/kg

Atorvastatin calcium

Rat/Mouse Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 5 of 8
Version: 3.0

11. TOXICOLOGICAL INFORMATION

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Atorvastatin calcium

Skin Sensitization - Beuhler Guinea Pig Negative
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Atorvastatin calcium

104 Week(s) Dog Oral 10 mg/kg/day LOAEL Liver
13 Week(s) Mouse Oral 100 mg/kg/day LOAEL Liver
52 Week(s) Rat Oral 5 mg/kg/day NOAEL Liver
13 Week(s) Rat Oral 5 (male); 20 (female) mg/kg/day NOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Atorvastatin calcium

Reproductive & Fertility Rat Oral 20 mg/kg/day NOAEL Negative
Fertility and Embryonic Development Rat Oral 100 mg/kg/day NOAEL Negative
Embryo / Fetal Development Rat Oral 100 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity
Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity, Fetotoxicity
Peri-/Postnatal Development Rat Oral 20 mg/kg/day NOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Atorvastatin calcium

In Vitro Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
In Vivo Micronucleus Mouse Bone Marrow Negative

Mutagenicity No evidence of mutagenic or clastogenic activity in in vitro or in vivo tests.

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Atorvastatin calcium

104 Week(s) Mouse Oral 200 mg/kg/day NOAEL Not carcinogenic
104 Week(s) Rat Oral 100 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:

In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil. Not readily biodegradable. May have harmful effects on the aquatic environment. May persist in the aquatic environment. Releases to the environment should be avoided.

Mobility, Persistence and Degradability:

<10% biodegraded in 28 days (atorvastatin calcium)

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 6 of 8
Version: 3.0

12. ECOLOGICAL INFORMATION

Atorvastatin calcium

Daphnia magna (Water Flea) EC50 48 Hours 200 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 92 mg/L
Pseudokirchneriella subcapitata (Green Alga) OECD EbC50 72 Hours 75 mg/L
Daphnia magna (Water Flea) OECD NOEC 21 Days 0.14 mg/L
Pimephales promelas (Fathead Minnow) OECD NOEC 32 Days 0.45 mg/L

Aquatic Toxicity Comments: The (21) day (LOEC) study above is a reproductive/survival study. The 32 day study above is an Early Life-Stage Toxicity test. A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Atorvastatin calcium

Aspergillus niger (Fungus) MIC > 1000 mg/L
Trichoderma viride (Fungus) MIC > 1000 mg/L
Clostridium perfringens (Bacterium) MIC 100 mg/L
Activated sludge OECD EC50 >1000 mg/L

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 7 of 8
Version: 3.0

15. REGULATORY INFORMATION

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Simethicone emulsion

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

Lactose NF, monohydrate

Australia (AICS):	Present
-------------------	---------

Calcium carbonate

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	207-439-9

Croscarmellose sodium

Australia (AICS):	Present
-------------------	---------

Hydroxypropyl cellulose

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-674-9

Polysorbate 80

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 12 - Ecological Information.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

MATERIAL SAFETY DATA SHEET

Material Name: Lipitor® (Atorvastatin Calcium) Tablets
Revision date: 07-Sep-2011

Page 8 of 8
Version: 3.0

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet